The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study
BackgroundWhile the BST1 rs4698412 variant demonstrates a robust association with Parkinson’s disease (PD) susceptibility, its role in modulating PD progression remains unexplored.ObjectivesTo evaluate differences in the progression of motor symptoms and cognitive function between PD patients carryi...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2025.1570347/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182681435832320 |
|---|---|
| author | Hao-Ling Xu Hao-Ling Xu Yu Yang Yu Yang Yu Yang Li-Na Chen Li-Na Chen Yun-Jing Li Yun-Jing Li Guo-En Cai Guo-En Cai Ying-Qing Wang Ying-Qing Wang Yan-Hong Weng Yan-Hong Weng Xiao-Ling Lin Xiao-Ling Lin Jing Jian Jing Jian Xiao-Chun Chen Xiao-Chun Chen Qin-Yong Ye Qin-Yong Ye |
| author_facet | Hao-Ling Xu Hao-Ling Xu Yu Yang Yu Yang Yu Yang Li-Na Chen Li-Na Chen Yun-Jing Li Yun-Jing Li Guo-En Cai Guo-En Cai Ying-Qing Wang Ying-Qing Wang Yan-Hong Weng Yan-Hong Weng Xiao-Ling Lin Xiao-Ling Lin Jing Jian Jing Jian Xiao-Chun Chen Xiao-Chun Chen Qin-Yong Ye Qin-Yong Ye |
| author_sort | Hao-Ling Xu |
| collection | DOAJ |
| description | BackgroundWhile the BST1 rs4698412 variant demonstrates a robust association with Parkinson’s disease (PD) susceptibility, its role in modulating PD progression remains unexplored.ObjectivesTo evaluate differences in the progression of motor symptoms and cognitive function between PD patients carrying the BST1 rs4698412 A-allele variant and GG homozygotes.MethodsBaseline clinical data were collected during their initial visits. Disease severity was assessed using the UPDRS-III scale, while cognitive status was evaluated through the MMSE scale. Follow-up visits were conducted at the same center. Linear mixed-effects models were utilized to compare the rate of changes in motor and cognitive features between the two groups.ResultsA total of 182 PD patients with 74 classified as GG carriers and 108 as GA/AA carriers were enrolled. No significant differences were observed in baseline demographic factors or clinical characteristics. Linear mixed-effects models revealed that GA/AA carriers exhibited a greater rate of change in UPDRS-III score compared with GG carriers (difference of −2.091[0.691] points per year, P = 0.003). However, no statistically significant difference in the estimated progression rate of MMSE score was found between the two groups (difference of −0.106 [0.217] points per year, P = 0.627).ConclusionPD patients carrying the BST1 rs4698412 A-allelic variant showed more pronounced motor function deterioration than GG carriers, suggesting that BST1 rs4698412 may serve as a genetic risk factor for disease progression in PD. |
| format | Article |
| id | doaj-art-2f59d2d32c5e4931803d8e628c5da86e |
| institution | OA Journals |
| issn | 1663-4365 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj-art-2f59d2d32c5e4931803d8e628c5da86e2025-08-20T02:17:34ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652025-04-011710.3389/fnagi.2025.15703471570347The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal studyHao-Ling Xu0Hao-Ling Xu1Yu Yang2Yu Yang3Yu Yang4Li-Na Chen5Li-Na Chen6Yun-Jing Li7Yun-Jing Li8Guo-En Cai9Guo-En Cai10Ying-Qing Wang11Ying-Qing Wang12Yan-Hong Weng13Yan-Hong Weng14Xiao-Ling Lin15Xiao-Ling Lin16Jing Jian17Jing Jian18Xiao-Chun Chen19Xiao-Chun Chen20Qin-Yong Ye21Qin-Yong Ye22Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fuzhou First General Hospital Affiliated with Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaDepartment of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, ChinaBackgroundWhile the BST1 rs4698412 variant demonstrates a robust association with Parkinson’s disease (PD) susceptibility, its role in modulating PD progression remains unexplored.ObjectivesTo evaluate differences in the progression of motor symptoms and cognitive function between PD patients carrying the BST1 rs4698412 A-allele variant and GG homozygotes.MethodsBaseline clinical data were collected during their initial visits. Disease severity was assessed using the UPDRS-III scale, while cognitive status was evaluated through the MMSE scale. Follow-up visits were conducted at the same center. Linear mixed-effects models were utilized to compare the rate of changes in motor and cognitive features between the two groups.ResultsA total of 182 PD patients with 74 classified as GG carriers and 108 as GA/AA carriers were enrolled. No significant differences were observed in baseline demographic factors or clinical characteristics. Linear mixed-effects models revealed that GA/AA carriers exhibited a greater rate of change in UPDRS-III score compared with GG carriers (difference of −2.091[0.691] points per year, P = 0.003). However, no statistically significant difference in the estimated progression rate of MMSE score was found between the two groups (difference of −0.106 [0.217] points per year, P = 0.627).ConclusionPD patients carrying the BST1 rs4698412 A-allelic variant showed more pronounced motor function deterioration than GG carriers, suggesting that BST1 rs4698412 may serve as a genetic risk factor for disease progression in PD.https://www.frontiersin.org/articles/10.3389/fnagi.2025.1570347/fullgenetic riskmotor progressioncognitionBST1 rs4698412Parkinson’s diseaseneurodegeneration |
| spellingShingle | Hao-Ling Xu Hao-Ling Xu Yu Yang Yu Yang Yu Yang Li-Na Chen Li-Na Chen Yun-Jing Li Yun-Jing Li Guo-En Cai Guo-En Cai Ying-Qing Wang Ying-Qing Wang Yan-Hong Weng Yan-Hong Weng Xiao-Ling Lin Xiao-Ling Lin Jing Jian Jing Jian Xiao-Chun Chen Xiao-Chun Chen Qin-Yong Ye Qin-Yong Ye The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study Frontiers in Aging Neuroscience genetic risk motor progression cognition BST1 rs4698412 Parkinson’s disease neurodegeneration |
| title | The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study |
| title_full | The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study |
| title_fullStr | The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study |
| title_full_unstemmed | The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study |
| title_short | The impact of BST1 rs4698412 variant on Parkinson’s disease progression in a longitudinal study |
| title_sort | impact of bst1 rs4698412 variant on parkinson s disease progression in a longitudinal study |
| topic | genetic risk motor progression cognition BST1 rs4698412 Parkinson’s disease neurodegeneration |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2025.1570347/full |
| work_keys_str_mv | AT haolingxu theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT haolingxu theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yuyang theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yuyang theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yuyang theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT linachen theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT linachen theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yunjingli theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yunjingli theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT guoencai theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT guoencai theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yingqingwang theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yingqingwang theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yanhongweng theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yanhongweng theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaolinglin theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaolinglin theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT jingjian theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT jingjian theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaochunchen theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaochunchen theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT qinyongye theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT qinyongye theimpactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT haolingxu impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT haolingxu impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yuyang impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yuyang impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yuyang impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT linachen impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT linachen impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yunjingli impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yunjingli impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT guoencai impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT guoencai impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yingqingwang impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yingqingwang impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yanhongweng impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT yanhongweng impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaolinglin impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaolinglin impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT jingjian impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT jingjian impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaochunchen impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT xiaochunchen impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT qinyongye impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy AT qinyongye impactofbst1rs4698412variantonparkinsonsdiseaseprogressioninalongitudinalstudy |